Podcasts about glaxosmithkline gsk

  • 50PODCASTS
  • 59EPISODES
  • 29mAVG DURATION
  • 1EPISODE EVERY OTHER WEEK
  • Dec 15, 2022LATEST

POPULARITY

20152016201720182019202020212022


Best podcasts about glaxosmithkline gsk

Latest podcast episodes about glaxosmithkline gsk

Pharmacist Diaries
080 Anthea Pryde: Opportunities don't just happen, you create them!

Pharmacist Diaries

Play Episode Listen Later Dec 15, 2022 72:54


On this week's episode, I am delighted to showcase the journey of a newly qualified pharmacist, Anthea Pryde. Anthea graduated from Kings College London (KCL) in 2019 and then successfully completed her trainee pharmacist year split between Lloyds Pharmacy and GlaxoSmithKline (GSK). She is currently employed as a Supply Chain Study Lead at GSK and enjoying the start of her pharmacy career. What attracted me to inviting Anthea onto the podcast was her enthusiasm and curiosity to learning and exploring what pharmacy has to offer whilst she was a student. During her life student life, she definitely made the most of the opportunities around her and she tells us all about the benefits of doing this during our conversation. Below are some of the experiences and placements she enjoyed as a student: A 3-month research internship role at Pfizer UK as part of Anthea's final year dissertation project. Project title: ‘Influence of punch tip surfaces on API adhesion' (2018) A 6-week Editorial intern at PharmPress supporting updates to the British National Formulary (BNF) and Martindale Drug Reference texts (2018) Summer Placement at Royal Brompton and Harefield NHS Foundation Trust (2018) Summer International Pharmaceutical Students Federation (IPSF) Research Internship Programme (Massachusetts College of Pharmacy and Healthcare Sciences, Boston, USA) (2017) Summer placement at Lloyds pharmacy (2016) We talk in depth about how the transferrable skills from these experiences helped her with applications and interviews, with specific reference to getting offered an industry trainee pharmacist position with very limited experience in that sector of pharmacy. Linkedin: @Anthea Pryde Follow me on YouTube, Instagram, Facebook, LinkedIn, and/or Twitter. Feel free to subscribe to the podcast on your favourite podcast platform so you can be notified when a new episode is released or leave a review on apple podcasts. If you have any suggestions for guests you want me to talk to or if you'd like to come on yourself, please feel free to contact me via social media, or email at info@pharmacistdiaries.com.

Biotech 2050 Podcast
131. Epigenetic approaches to rare diseases, Amber Salzman, CEO, Epic Bio

Biotech 2050 Podcast

Play Episode Listen Later Dec 14, 2022 24:20


Synopsis: Amber Salzman is the CEO of Epic Bio, a company that develops therapies to dynamically control gene expression and treat complex diseases. Dr. Salzman started her career in big pharma at GlaxoSmithKline before transitioning to the biotech industry and focusing on rare diseases. In this episode, she sits down with host Rahul Chaturverdi to discuss her learnings from moving from big pharma to biotech, how her roles differ from being a CEO vs. being a board member, her perspective on pursuing interesting technology in biotech, the work Epic Bio is doing in the gene therapy space, and the role of patient advocacy in early stage biotechs. Biography: Amber Salzman, Ph.D., is Epic Bio's chief executive officer and director. Dr. Salzman is a leader with more than 30 years of experience in the pharmaceuticals industry. Before joining Epic Bio, Dr. Salzman served as the president and CEO of Ohana Biosciences, pioneering the industry's first sperm biology platform. Before Ohana, she served as the president and CEO of Adverum Biotechnologies and was a co-founder of Annapurna, SAS, where she served as president and CEO before its merger with Avalanche Biotechnologies to become Adverum. In that role, she saw the company's stock price double. Dr. Salzman began her career as a member of the GlaxoSmithKline (GSK) research and development executive team, where she was responsible for operations in drug development across multiple therapeutic areas, overseeing global clinical trials with over 30,000 enrolled patients, managing 1,600 employees and a $1.25B budget. Following her time at GSK, Dr. Salzman served as the CEO of Cardiokine, a pharmaceutical company that developed treatments for the prevention of cardiovascular diseases and saw the successful sale of the company to Cornerstone Therapeutics. Dr. Salzman currently serves on the Osler Diagnostics (UK) and AviadoBio (UK) Boards. Dr. Salzman received her bachelor's degree from Temple University and holds a Ph.D. in mathematics from Bryn Mawr College. In addition to advocating for patients living with rare diseases, Dr. Salzman leads the Stop ALD Foundation, a non-profit medical research foundation focused on developing novel gene therapies for adrenoleukodystrophy (ALD).

Investors Chronicle
The Companies and Markets show: GSK, Private Equity Trusts, and two more hot Aim stocks

Investors Chronicle

Play Episode Listen Later Nov 4, 2022 28:12


On this week's episode, Dan Jones welcomes Jennifer Johnson to talk GlaxoSmithKline (GSK) - they've made a good start to life post Haleon split, but are they a one-trick pony at the moment?Then Mark Robinson dives back into the Aim 100, with two more interesting stocks from our special review of the top 100 companies in Aim (by market capitalisation).And finally, Val Cipriani makes her podcast debut with a look at private equity trusts.Dan Jones hosts Jennifer Johnson, Val Cipriani and Mark Robinson.-This podcast is sponsored by TILLIT. TILLIT is the investment platform for investors who want to make better investment decisions. Invest in a curated selection of funds, investment trusts and ETFs and get expert insights on each and every one. Hosted on Acast. See acast.com/privacy for more information.

FD Dagkoers
De vrije val van het Britse pond

FD Dagkoers

Play Episode Listen Later Sep 27, 2022 15:02


Topman Alan Jope vertrekt bij Unilever. Hij kondigde aan dat hij eind 2023 met pensioen gaat. Retailredacteur Jan Braaksma vertelt dat de achterblijvende koers van het bedrijf en de mislukte overname van de consumentendivisie van GlaxoSmithKline (GSK) voor deuken in het vertrouwen in de topman hebben gezorgd. Lees: Unilever-topman Alan Jope met pensioen na mislukte miljardenovername Het Britse pond is in een vrije val terechtgekomen. De munt stond gisteren op het laagste punt sinds 1985. De daling kwam na twijfels over de economische koers van de nieuwe Britse regering. Correspondent in het Verenigd Koninkrijk Joost Dobber vertelt dat de regering £45 mrd aan belastingverlagingen wil doorvoeren, bovenop de energiesteun die £60 mrd zal kosten. Lees: Bank of England weet val van pond niet te stoppen Nog niet zo lang geleden leek het erop dat de prijs van ruwe olie voorlopig hoog zou blijven. Maar een vat ruwe Brent-olie stond maandag kortstondig onder de $85 per vat, de laagste prijs sinds januari. Redacteur financiële markten Jeroen Groot vertelt dat de angst voor een recessie en de sterke Amerikaanse dollar de grootste oorzaken van de prijsdaling zijn. Lees: Olieprijs duikt door overschotten onder de $85 per vatSee omnystudio.com/listener for privacy information.

Der Krebs Podcast
Langzeitüberlebende nach der Diagnose Gebärmutterkörperkrebs

Der Krebs Podcast

Play Episode Listen Later Sep 22, 2022 16:43


Wie wird das Leben nach dem Krebs? Dr. med. Woppen gibt einen Einblick in die Langzeitfolgen von Krebs. Viele Krebserkrankungen sind heute bereits heilbar und das Leben nach dem Krebs rückt immer mehr in den Fokus. Was heißt eigentlich überhaupt überleben bei einer Krebserkrankung? wenn ich länger als fünf Jahre ohne wiederkehrende Erkrankung lebe, dass ich dann davon geheilt bin? Wie erkennt man denn dann das Rezidiv und wie sieht die Nachsorge aus beim Gebärmutterkörperkrebs?GICG: https://gcigtrials.org/Studien Portal: www.studienportal-gyn.deWebseite: https://www.krebs-podcast.deSprechstunde Langzeitüberlebende: https://survivorship-clinic.de/ Referenten:Dr. med. Hannah Woopen, MSc (Fachärztin, Charité – Universitätsmedizin Berlin, Schwerpunkt: Langzeitüberleben bei Patientinnen mit Ovarialkarzinom (Studienleiterin "Carolin meets HANNA"), Junior Clinical Scientist, Master of Science - Clinical Research)Dr. med. Robert Armbrust (Oberarzt, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin) Erfahren Sie in dieser von vier Folgen alles zum Thema Leben mit dem Krebs. Erste Folgen zu der Serie Endometrium Karzinom: Folge 13-15. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich. Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten.Die meisten Patienten mit Endometriumkarzinom überleben zehn Jahre, aber die Krebserkrankung ist nicht der einzige Faktor, der berücksichtigt werden muss. Nach fünf Jahren sollten keine Rezidive mehr auftreten, aber es kann vorkommen, dass nach fünf, zehn oder sogar fünfzehn Jahren doch ein Rezidiv auftritt.Die GSIG hat sich darauf geeinigt, dass Langzeitüberleben mit gynäkologischen Tumoren als Überleben von mindestens fünf Jahren gilt.Die meisten Frauen mit Endometriumkarzinom sterben nicht an Krebs, sondern an Herzkrankheiten. Es ist wichtig, dass Sie Ihre Gesundheitskompetenz stärken, um zu verhindern, dass Sie erneut an Krebs erkranken. Man sollte sich von einem Expertenteam behandeln lassen und sich auch eine zweite Meinung einholen, wenn man an Krebs erkrankt ist.Die neuen Medikamente zur Immuntherapie von Krebs werden wahrscheinlich einen großen Einfluss auf die Prognose haben, aber die Langzeitnebenwirkungen sind noch nicht bekannt.Viele Frauen, die wegen Endometriumkrebs behandelt wurden, haben Probleme mit der sexuellen Funktion, was die Lebensqualität erheblich beeinträchtigen kann. Auch Osteoporose ist eine häufige Nebenwirkung der Krebsbehandlung.Die Deutsche Krebsgesellschaft hat Verzeichnisse von Zentren, an die man sich wenden kann, und der Langzeitüberlebendenschwerpunkt in der Survivorship Klinik in Berlin ist empfehlenswert.#fernmetastasen #rezidiv #ASCO #GICG #survivorship #cancersurvivor Hosted on Acast. See acast.com/privacy for more information.

Der Krebs Podcast
Gebärmutterkörperkrebs Rezidiv

Der Krebs Podcast

Play Episode Listen Later Sep 15, 2022 24:37


Rezidiv Therapie bekommt immer einen höheren Stellenwert in der Medizin. Mediziner, aber auch Sie als Angehörige und Patientinnen wissen, dass eine der Hauptsorgen bei einer Krebserkrankung ist: Kommt der Krebs wieder? Und wie wird das Rezidiv eigentlich erkannt? Deswegen wollen wir uns heute damit beschäftigen: Wie erkennt man das Rezidiv? Und was haben wir für therapeutische Möglichkeiten? Was bedeutet Immuntherapie? Ist es denn tatsächlich so, dass über die Nachsorge die meisten Rezidiv erkannt werden? Was sind was die wichtigsten und häufigsten Symptome, wie Luftnot, Schmerzen im Bein, Blutung, Nierenschmerzen, Ausfluss?Studien Portal: www.studienportal-gyn.deWebseite: https://www.krebs-podcast.deReferenten:Prof. Dr. med. Dr. h.c. Sehouli (Direktor der Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie (CVK) und Klinik für Gynäkologie (CBF), Charité Berlin)Dr. med. Robert Armbrust (Oberarzt, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin)Erfahren Sie in dieser von vier Folgen alles Rezidiv Therapie des Gebärmutterkörperkrebses. Erste Folgen zu der Serie Endometrium Karzinom: Folge 13-14. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich. Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten.In dieser Podcast-Episode wird über das Rezidiv von Gebärmutterkörperkrebs und die Möglichkeiten der Therapie gesprochen Nachsorge ist wichtig, sollte länger als 5 Jahre sein, und kann viele Jahre später auftreten. Trotz aller Vorsorge, können Tumoren in der Nachsorge wieder entdeckt werden. Daher sollten Patienten mit Beschwerden nicht erst auf den Termin in der Nachsorge warten, sondern das abklären lassen. Das Wichtigste ist, dass man daran denkt, nicht alle in Panik bringt, aber dann Schritt für Schritt nach untersucht. Die Diagnose eines Tumors erfolgt in der Regel durch eine Kombination aus verschiedenen Untersuchungsmethoden, Ultraschall, Computertomografie und Magnetresonanztomografie. Die Blutwerte sind nicht immer ausschlaggebend. Untersuchungen sollten nur bei Bedarf durchgeführt werden, um Schäden durch unnötige Röntgenstrahlung zu vermeiden. Die routinemäßige Verwendung von Computertomografie bei Patientinnen, die wegen eines Tumors operiert wurden, ist sinnlos. Die Ultraschalluntersuchung des Bauches und der und über die Scheide sollten Standard sein. Die Immuntherapie ist ein großes Thema, weil wir immer mehr lernen, dass das Immunsystem nicht nur die klassischen weißen Blutkörperchen sind, sondern alle Zellen, die letztlich mehr oder weniger das Immunsystem mit positiv beeinflussen, direkt und indirekt. Inzwischen kann man bei vielen Tumoren, inklusive Gebärmutterkörperkrebs, eine chemotherapiefreie Therapiestrategie anwenden. Immuntherapie ist eine neue Art der Krebstherapie, die das Immunsystem des Patienten gegen den Krebs richtet die auch in der Behandlung von Hautkrebs wie auch bei anderen Tumoren, inklusive Gebärmutterkörperkrebs eine Revolution ist. Es gibt verschiedene Arten der Immuntherapie, die für verschiedene Situationen zugelassen sind. Ob eine Person für eine bestimmte Art der Immuntherapie geeignet ist, hängt von verschiedenen Faktoren ab. Dazu sind Studien auch bei Ersttherapie im Gange. Hosted on Acast. See acast.com/privacy for more information.

TD Ameritrade Network
GSK, BK, CAG: Stocks To Watch During High Inflation

TD Ameritrade Network

Play Episode Listen Later Sep 13, 2022 6:52


The CPI report shows that food isn't moving down as quickly as hoped, says James Locke. He discusses the chances of a full point rate hike next week. He also asks if there could be a market rally after the Fed raises rates. He also talks about how inflation is going down slowly but it is going down. He then goes over some of his stocks to watch which include GlaxoSmithKline (GSK), Bank of New York (BK), and Conagra (CAG). Tune in to find out more about the stock market today.

Der Krebs Podcast
Vorbereitung vor der Krebstherapie

Der Krebs Podcast

Play Episode Listen Later Sep 8, 2022 29:01


Gebärmutterkörperkrebs kann einen sehr beunruhigenden und verwirrenden Zeitpunkt darstellen. Viele Patientinnen haben viele Fragen und wissen nicht, wo sie anfangen sollen. Patientinnen fragen sich oft, was sie selbst machen können, um die Behandlung zu unterstützen. Wie findet man eigentlich das richtige Zentrum? Wo finde ich Informationen über Studien zum Gebärmutterkörperkrebs. In dieser Podcastfolge möchten wir einige Tipps und Hinweise geben, worauf Sie vor und während einer Krebstherapie achten sollten. Dazu gehört zum Beispiel, sich über die verschiedenen Behandlungsmöglichkeiten zu informieren und herauszufinden, welche für Sie die Beste ist. Sie sollten auch einen Ernährungsplan erstellen, um sicherzustellen, dass Sie während der Behandlung ausreichend Nährstoffe zu sich nehmen. Alle Disziplinen in den Behandlungsplan einbeziehen. Studien Portal: www.studienportal-gyn.deWebseite: www.krebs-podcast.de Referenten:Prof. Dr. med. Dr. h.c. Jalid Sehouli (Direktorder Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie (CVK) undKlinik für Gynäkologie (CBF), Charité Berlin)Dr. med. Robert Armbrust (Oberarzt, Klinik fürGynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin) Erfahren Sie in dieser von vier Folgen alles über alles über die Vorbereitung auf die Therapie des Gebärmutterkörperkrebses.Erste Folge der Gebähmutterkrebs-Serie über die neuesten Entwicklungen in der Diagnostik und Therapie des Gebärmutterkörperkrebses. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich.Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

OffScrip with Matthew Zachary
[BEST OF OOP] Dr.Tania Small: GYN/ONC Cancer's Unmet Needs

OffScrip with Matthew Zachary

Play Episode Listen Later Sep 1, 2022 24:43


Original Air Date 3/16/2022 — Dr. Tania Small is the Vice President and Global Medical Oncology Head at GSK. She started her career as a pediatric oncologist and realized that her passion for helping patients would drastically accelerate by transitioning to the R&D side of healthcare. She did just that, as you'll hear in this episode when she describes how it felt to see her first FDA-approved medication prescribed to treat thousands more patients than she could have ever helped individually. Her latest passion is serving the GYN/ONC research community and sharing with Matthew the many new challenges and opportunities industry is tackling head-on to put the patient more at the center of care. Also, what role can women take in getting ahead of these diseases, and how can we collaborate to help patients survive and thrive? Also, what does she see as the most revolutionary biotech innovations on the horizon for women living with cancer? Medical progress can only do so much if patients have trouble accessing care, and Covid-19 has made us painfully aware of the racial and socioeconomic gaps in healthcare access. How do we break down those access barriers and help underserved communities get the services they need?For more information, visit https://OffScrip.com and follow @MatthewZachary, and @OffScripHealth on Twitter.This ad-free episode of Out of Patients is made possible by our partner, GlaxoSmithKline(GSK), a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer. For more information, please visit https://www.gsk.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Der Krebs Podcast
Endometrium Karzinom - Diagnostik

Der Krebs Podcast

Play Episode Listen Later Aug 31, 2022 25:38


Gebärmutterkörperkrebs ist nach dem Brustkrebs die zweithäufigste Krebsart, die vorwiegend Frauen im reproduktiven Alter betrifft. Durch die Tatsache, dass wir Menschen immer älter werden und letztlich auch immer weniger bewegen, nimmt auch die Zahl der Frauen mit Gebärmutterkörperkrebs deutlich zu. Die Inzidenz ist steigend auf 11.000 Neuerkrankungen pro Jahr. Die Diagnose, Therapie und Nachsorge des Gebärmutterkörperkrebses sind komplex und bedürfen einer sorgfältigen Planung. In diesem Podcast geben Dr. med. Robert Armbrust (Link) und Prof. Dr. med. Dr. h.c. Jalid Sehouli (Link) einen Überblick über die entscheidenden Fragen in der Diagnostik, Therapie und Nachsorge des Endometriumkarzinom. Wir erleben durch die neuen Immuntherapien eine ganz neue Dynamik in der Behandlungsstrategie beim Gebärmutterkörperkrebs. Wo der Gebärmutterhalskrebs ist in Deutschland durch eine Vorsorgeuntersuchung Screening Untersuchung gut abgedeckt ist, erkennt man den Gebärmutterkörperkrebs an bestimmten Leitsymptomen. Gerade in der Therapie ist eine Abwägung von Strahlen, Chemo oder Immuntherapie je nach Risikogruppe unerlässlich. Unter anderem legen wir auch ein Hauptaugenmerk auf die Nachsorge, die gerade bei Gebärmutterkörperkrebs Patientinnen mit einem Nachsorge Konzept durchdacht sein sollte.Webseite: www.krebs-podcast.deReferenten:Prof. Dr. med. Dr. h.c. Jalid Sehouli (Direktor der Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie (CVK) und Klinik für Gynäkologie (CBF), Charité Berlin)Dr. med. Robert Armbrust (Oberarzt, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin)Erfahren Sie in dieser von vier Folgen alles über die neuesten Entwicklungen in der Diagnostik und Therapie des Gebärmutterkörperkrebses. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich. Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

Cyber Senate Podcast
The Checks and Balances for Cybersecurity Readiness

Cyber Senate Podcast

Play Episode Play 30 sec Highlight Listen Later Aug 25, 2022 37:46 Transcription Available


Cyber Senate had the privilege of catching up with Willi Nelson, CISO, Operational Technologies, Fortinet to discuss their forthcoming presentation on Cyber Preparedness September 29-30th in Celebration Florida, for the 9th annual Control System Cybersecurity USA conference.  Large or small, cyberattacks are making headlines and elevating executive attention toward cyber resiliency. Preparing for, responding to and recovering from cyberattacks should be a strategic part of any business continuity plan. As recent cyberattacks have demonstrated increased risk to both IT and operational technology (OT) environments, readiness equates to enforcement of rules and policies that provide the visibility, control and situational awareness to respond at the speed of business.  Cybercriminals are maximizing their opportunity by exploiting older vulnerabilities and an expanding attack surface. Strategic readiness should be underpinned with the notion that eventually an attack will happen, and when it occurs, you are proactively ready to respond. During this session, we will explore security considerations for developing cyber resilience covering security fundamentals and readiness planning to protect your IT and OT environments.Willi joined Fortinet as the CISO for Operational Technology in August 2022. He brings more than 25 years of experience in Information Security working across industry verticals such as Healthcare, Telecom, Financials, Manufacturing, and Life Sciences. Most recently with GlaxoSmithKline (GSK), he established and directed the Global OT Infrastructure Security team charged with monitoring and protecting the OT assets for GSK. Globally, the team deployed 43 additional controls across the OT landscape assessed against NIST CSF and aligned business units to embrace a unified model for security, incident response, and risk reporting. During Willi's tenure, he also oversaw the creation of the Security Organization and the Global Cyber Defense team for GSK's Consumer Health startup (now called Haleon). Beyond building and leading the OT and Consumer Health security teams, he led the security team responsible for Cloud transformation for both IT and OT. Willi relies on a pragmatic and systematic approach to achieve company goals while also maturing the organizations and teams he leads. Willi is a graduate of Rockhurst University in Kansas City, MO, USA and holds a CISSP (Certified Information Security Professional) certification in good standing. Willi lives in NW Arkansas with his family. He's an avid outdoorsman, cyclist, woodworker, and veteran.

The Tech Trek
Raj Madan - How to build empowered teams

The Tech Trek

Play Episode Listen Later Aug 23, 2022 21:53


Highlights of my conversation with Raj: Allowing teams to make decisions at the lowest possible level Empowerment is coupled with responsibility Make sure only the necessary stakeholders are in a meeting Always do the right thing for the customer and stakeholders Building out a learning culture Agile mindset shift Failing faster requires empowerment Focusing on measuring outcomes and not activities Meet: Raj Madan has over 20 years of digital transformation and innovation experience and is currently the CDIO at Arcutis Biotherapeutics. Before joining Arcutis, Raj served as the Vice President of Digital, Data/Analytics, and Innovation for Consumer Healthcare Technology at GlaxoSmithKline (GSK). In partnership with the Chief Digital Officer, he was responsible for driving significant elements of their Digital and Tech transformation globally. Before GSK, Raj was with Novartis. He was responsible for managing and delivering global, regional, and localized digital solutions and services across three business units and in more than 80 countries. In addition to healthcare, Raj has experience in the consumer goods sector, having spent 14 years at L'Oreal in various roles, including managing the digital tech function for L'Oreal Americas. Raj holds a bachelor's degree in computer engineering from the New Jersey Institute of Technology and a master's degree in business administration and information systems from New York University Stern School of Business. Raj is also an advisory board member at Onymos, an app development platform that helps developers and teams build brilliant apps faster. If you have any questions for Raj, please feel free to reach out via: https://www.linkedin.com/in/rajvir-raj-madan-3a74252 I hope you enjoyed the episode. The best place to connect with me is on Linkedin - https://www.linkedin.com/in/amirbormand (Amir Bormand). Please message me if you want me to cover specific topics with future guests.

Mass Tort News LegalCast
Gardasil Vaccine MDL 3606 with Bijan Esfandiari, a Post-JPML Hearing Update

Mass Tort News LegalCast

Play Episode Listen Later Aug 11, 2022 34:36


Bijan Esfandiari serves as Senior shareholder at Baum Hedlund Aristei & Goldman, litigating cases of pharmaceutical product liability. Bijan discusses his current MDL (No. 3036) against pharmaceutical company Merck for the production and distribution of Gardasil, an HPV vaccine believed to cause POTS. Esfandiari explains how the defense shames victims of the toxic vaccine into silence by labeling them “anti-vaxers.” Esfandiari also actively worked on the 2010 GlaxoSmithKline (GSK) litigation, which resulted in $750 million settlement in civil and criminal claims over the company's manufacturing of contaminated medication. Esfandiari received a unanimous agreement from a three-judge panel for his arguments in both the McCormick v. Medtronic, Inc. and Mason v. SmithKline Beecham Corp. With over 20 years of experience in law, Esfandiari holds great passion for helping others, specifically those harmed by large corporations. Bijan's most recent honors include being named to the 2022 of Best Lawyers in America®, Lawdragon's 2022 list of Leading Plaintiff Consumer Lawyers, and Law360's 2021 series of Regional Powerhouses in California. Bijan also received recognition on the Southern California Super Lawyers® list of Rising Stars annually since 2009. Esfandiari remains active in the law community outside of the courtroom by speaking at national law conferences and serving as a member of the pro-bono Representative Assembly of the Palms Neighborhood Council. Bijan maintains membership in the American Association for Justice's Leader's Forum, the Consumer Attorneys Association of Los Angeles, and UCLA Journal of International Law & Foreign Affairs. Bijan speaks fluent Farsi and conversational German.  Remember to subscribe and follow us on social media… LinkedIn: https://www.linkedin.com/company/mass-tort-news Twitter: https://www.twitter.com/masstortnewsorg Facebook: https://www.facebook.com/masstortnews.org

Progress, Potential, and Possibilities
Dr. Amber Salzman, PhD - CEO & Director, Epic Bio - Editing The Epigenome To Treat Complex Diseases

Progress, Potential, and Possibilities

Play Episode Listen Later Jul 28, 2022 38:34


Dr. Amber Salzman, Ph.D. is Chief Executive Officer and Director of Epic Bio (https://epic-bio.com/), a fascinating therapeutic epigenome editing startup, developing therapies to modulate gene expression at the level of the epigenome, which just recently emerged from stealth mode with a $55 million funding round. Dr. Salzman has more than 30 years of experience in the pharmaceuticals industry. Before joining Epic Bio, Dr. Salzman served as the president and CEO of Ohana Biosciences, pioneering the industry's first sperm biology platform. Before Ohana, she served as the president and CEO of Adverum Biotechnologies and was a co-founder of Annapurna, SAS, where she served as President and CEO before its merger with Avalanche Biotechnologies to become Adverum. In that role, she saw the company's stock price double. Dr. Salzman began her career as a member of the GlaxoSmithKline (GSK) research and development executive team, where she was responsible for operations in drug development across multiple therapeutic areas, overseeing global clinical trials with over 30,000 enrolled patients, managing 1,600 employees and a $1.25B budget. Following her time at GSK, Dr. Salzman served as the CEO of Cardiokine, a pharmaceutical company that developed treatments for the prevention of cardiovascular diseases and saw the successful sale of the company to Cornerstone Therapeutics. Dr. Salzman currently serves on the Osler Diagnostics (UK) and AviadoBio (UK) Boards. Dr. Salzman received her bachelor's degree from Temple University in computer science and holds a Ph.D. in mathematics from Bryn Mawr College. In addition to advocating for patients living with rare diseases, Dr. Salzman leads the Stop ALD Foundation, a non-profit medical research foundation focused on developing novel gene therapies for adrenoleukodystrophy (ALD).

En Perspectiva
Entrevista Bruno Guella - Centro de distribución de vacunas de GSK se instalará en Uruguay

En Perspectiva

Play Episode Listen Later May 25, 2022 17:34


La empresa farmacéutica británica GlaxoSmithKline (GSK) abrirá en Uruguay en los "próximos dos meses" uno de sus "tres nuevos centros regionales de distribución de vacunas", donde se colocarán más de "12 millones de vacunas al año en seis países de América del Sur", así dice declaración conjunta entre Reino Unido y Uruguay que informó el Ministerio de Relaciones Exteriores este martes, un día después del encuentro que mantuvieron Luis Lacalle Pou y Boris Johnson. El comunicado de Cancillería indica que tanto Lacalle Pou y Johnson "señalaron el enorme potencial de crecimiento de los vínculos comerciales y económicos y celebraron el anuncio de GSK sobre la apertura de uno de sus tres nuevos centros regionales de distribución de vacunas en Uruguay". "Este centro será inaugurado en los próximos dos meses, y desde el mismo se distribuirán más de 12 millones de vacunas al año en 6 países de América del Sur", agrega el comunicado, que no aporta más detalles de esta inversión. ¿Dónde estará este centro de GSK? En las instalaciones de Latin America Cargo City (LACC), la unidad de negocios que maneja las cargas de Corporación América en el predio del aeropuerto de Carrasco. Profundizamos en esta novedad y lo que ocurre en el aeropuerto. Conversamos En Perspectiva con Bruno Güella, CEO de Latin America Cargo City (LACC).

VOV - Việt Nam và Thế giới
Tin trong nước: Hệ thống tiêm chủng VNVC ký hợp tác chiến lược với Tập đoàn dược GLAXOSMITHKLINE - GSK (Bỉ) cam kết đưa thêm nhiều vắc xin mới về Việt Nam!

VOV - Việt Nam và Thế giới

Play Episode Listen Later May 11, 2022 1:41


- Sáng nay (11/5), tại TPHCM, Tập đoàn dược phẩm hàng đầu Thế giới GlaxoSmithKline - GSK (Bỉ) và Hệ thống trung tâm tiêm chủng VNVC đã ký kết biên bản ghi nhớ hợp tác chiến lược toàn diện và lâu dài về cung ứng vắc xin, mở ra cơ hội để VNVC đưa về Việt Nam nhiều loại vắc xin mới, vắc xin khan hiếm với số lượng lớn tiêm chủng cho người dân. --- Support this podcast: https://anchor.fm/vov1tintuc/support

TD Ameritrade Network
Inflation Returning To Normal In 2024 & Stocks To Invest In: MTB, GSK

TD Ameritrade Network

Play Episode Listen Later May 10, 2022 7:58


Will inflation return to normal in 2024, and will a recession occur? Value stocks outperformed growth stocks in April. M&T Bank (MTB) stock price is up almost 5% year-to-date. "M&T Bank recently acquired Peoples Bank. Will the company raise expectations following the merger? MTB reported above-consensus results," says James Locke. Also, the GlaxoSmithKline (GSK) stock price is up over 13% this past year. "The pharmaceutical and healthcare products company trades at 14.6X 2022 EPS and pays a 5.3% dividend rate. The company expects mid-single-digit sales growth and high single to low double-digit EPS growth going forward," Locke adds.

The Cannabis Conversation | Medical Cannabis | CBD | Hemp
EPISODE #161 Cannabis Vs. Opioids with Valentino Parravicini, Chief Scientific Officer at Oxford Cannabinoid Technologies

The Cannabis Conversation | Medical Cannabis | CBD | Hemp

Play Episode Listen Later Apr 5, 2022 43:00


This week, we're joined by Valentino Parravicini, Chief Scientific Officer at Oxford Cannabinoid Technologies - British pharmaceutical company developing a portfolio of next-generation prescription cannabinoid medicines.In this episode, we explore the potential use of cannabis-based medicines as a replacement for prescription opioids, their safety profile, and their use cases as analgesics. 

OffScrip with Matthew Zachary
[BONUS] Dr.Tania Small: GYN/ONC Cancer's Unmet Needs

OffScrip with Matthew Zachary

Play Episode Listen Later Mar 16, 2022 25:25


Dr. Tania Small is the Vice President and Global Medical Oncology Head at GSK. She started her career as a pediatric oncologist and realized that her passion for helping patients would drastically accelerate by transitioning to the R&D side of healthcare. She did just that, as you'll hear in this episode when she describes how it felt to see her first FDA-approved medication prescribed to treat thousands more patients than she could have ever helped individually. Her latest passion is serving the GYN/ONC research community and sharing with Matthew the many new challenges and opportunities industry is tackling head-on to put the patient more at the center of care. Also, what role can women take in getting ahead of these diseases, and how can we collaborate to help patients survive and thrive? Also, what does she see as the most revolutionary biotech innovations on the horizon for women living with cancer? Medical progress can only do so much if patients have trouble accessing care, and Covid-19 has made us painfully aware of the racial and socioeconomic gaps in healthcare access. How do we break down those access barriers and help underserved communities get the services they need? This ad-free episode of Out of Patients is made possible by our partner, GlaxoSmithKline(GSK), a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer. For more information, please visit https://www.gsk.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Column Corné van Zeijl | BNR
Opinie | Noodsprong Unilever

Column Corné van Zeijl | BNR

Play Episode Listen Later Jan 21, 2022 3:47


Unilever staat al een tijdje onder druk. Onder het tienjarige regime van Paul Polman bleven de winsten hopeloos achter bij de concurrentie. Zijn duurzame missie klonk destijds erg sympathiek, maar leverde geen winst op. Zijn opvolger, Alan Jope, heeft daar nog geen verandering in kunnen brengen. De golf van kritiek onder beleggers zwol steeds verder aan, en dat is in de koers terug te zien: die is flink bij de sectorgenoten achtergebleven. Het management besloot daarom een grote sprong voorwaarts te maken. Het deed een bod van £50 mrd op de consumententak van GlaxoSmithKline (GSK) - terwijl Unilever zelf slechts £100 mrd waard is - en ook nog eens tegen een superwaardering. De analistenramingen die ik voorbij zag komen, geven een GSK-waardering die ongeveer 50% hoger is dan die van Unilever. Dat leidt tot een enorme verwatering en dat werd gelijk ingeprijsd: het aandeel kelderde aanzienlijk. Beleggers vreesden nog hogere biedingen, maar haalden opgelucht adem toen Unilever aangaf dat £50 mrd wel even genoeg was. De kans dat de deal nu nog doorgaat, wordt erg klein geacht. Hoe wilde Unilever deze deal eigenlijk succesvol maken? In eerste instantie door kostenbesparingen. Die mogelijkheden lijken mij beperkt, GSK wordt al redelijk efficiënt gerund. Samen met GSK zou Unilever tandpastakoning worden. Maar hoe kun je die positie als marktleider uitnutten? Hoeveel kosten wil je hiermee besparen? Omzetsynergieën zijn er ook beperkt. Het voordeel moet vooral uit de financiële hefboom komen. Als je leent tegen bijna 0% rente, werkt dat al snel. De schuldratio gaat dan van twee keer het bedrijfsresultaat naar vier keer. Dan ben je eigenlijk een beetje private equity aan het spelen. Natuurlijk zou Unilever een deel van de overgenomen activiteiten weer doorverkopen. Maar als je iets heel graag wil hebben, dan betaal je de hoofdprijs. En als je dan later iets graag kwijt wil, gaat dat meestal tegen een discount. Iedereen weet immers dat je moet verkopen. Wat me overigens wel aan deze dealaankondiging opviel, is de bescheiden interesse van de media. Als Unilever nog Nederlands was geweest, dan zou het op alle voorpagina's hebben gestaan. Nu stond het ergens op pagina 16. Het is duidelijk dat Nederland emotioneel afscheid heeft genomen van Unilever, en voor beleggers geldt hetzelfde. Of de deal uiteindelijk doorgaat of niet, deze move brengt de magere operationele prestaties voor het voetlicht. Er zijn overigens partijen die wel graag dit soort berichten lezen. Voor Unilever is het spel op de wagen. De grote private-equitypartijen zullen hun spreadsheets laten ratelen. Ik ben benieuwd of de uitkomsten interessant genoeg zijn. Over de column van Corné van Zeijl Corné van Zeijl is analist en strateeg bij vermogensbeheerder Actiam en belegt ook privé. Reageer via corne.vanzeijl@actiam.nl. Deze column kun je ook iedere donderdag lezen in het FD.See omnystudio.com/listener for privacy information.

每日一經濟學人 LEON x The Economist
*第五季*【EP. 277】#684 經濟學人導讀 feat. 國際時事 feat. 新聞評論【GSK 的 Sotrovimab (新冠妙方?);羅興亞人 vs. 臉書 > 不作為也有錯;阿聯酋的週末有貓膩;充電樁遇到大瓶頸】

每日一經濟學人 LEON x The Economist

Play Episode Listen Later Dec 14, 2021 32:45


piworld audio investor podcasts
PIWORLD interview with Andy Brough: Markets & Lessons Learned in 2021

piworld audio investor podcasts

Play Episode Listen Later Dec 9, 2021 45:57


A tremendous interview that gives some insight to the highs and lows of 2021. What companies and Andy have learned through Covid. The hunt for disrupters. Activists and bid activity. The attractions of the FTSE100. We hear how an institution exits a position. The attractiveness of an IPO, a placing or an overhang. Director buys and sells. Latterly, we discuss bitcoin and NFT's (Non Fungible Tokens). Finally, for those who want the investing challenge (or fancy themselves as a Fund Manager!), we discuss the new PIWORLD series, Sell it to the City, and what the Fund Managers, Andy, Judith and Stephen are looking for from contestants. Please contact PIWORLD.CO.UK if you want to take part. A very engaging and informative listen. Thank you Andy! 01:02 How has 2021 been? 01:46 Omicrom? 03:28 Views on a Santa rally? 05:18 Inflation 07:05 Tapering 08:17 Disrupters Reach #RCH, Future #FUTR, Lookers #LOOK, Inchcape #INCH 12:15 Property - Grainger #GRI 13:11 FTSE100, FTSE250 v AIM Royal Mail #RMG; Land Securities #LAND; #WISE, Marks & Spencer #MKSN 17:18 Activists: Elliot, Glaxosmithkline #GSK, Taylor Wimpey #TW., Clinigen #CLIN, Pearson #PSON, Johnson Matthey #JMAT 17:50 Which holdings which will move the dial? Frasers #FRAS, Studio Retail #STU 19:00 Bid activity Clinigen #CLIN 19:47 Studio Retail #STU 22:43 Learnings from 2021 25:22 Tremor #TRMR 26:47 Bid pick for 2022 Indivior #INDV 28:39 Crystal Amber and selling an overhang #DLAR 30:57 Institutional pools of liquidity & IPOs 32:18 Preference to buy and IPO, placing or overhang? 34:18 Evolution of Covid: what went well and what went badly 37:44 Director buys and sells Telecom Plus #TEP; Tremor #TRMR Fraser #FRAS 40:19 Bitcoin 41:40 NFTs 42:14 Where to find Andy Brough & his funds 42:41 Sell it to the City: what is it? What the Fund Managers want to hear. (Sell it to the City - Episode 1: https://www.piworld.co.uk/education-videos/piworld-sell-it-to-the-city-october-2021/) About Andy Brough: • Head of the UK & European Small and Mid Cap team • Manager of the Schroder Mid 250 Fund and the Schroder UK Smaller Companies Fund • Co-Manager of the Schroder UK Mid Cap Fund plc and Co-manager of the Schroder Institutional UK Smaller Companies Fund • Co-manager of Schroder ISF European Smaller Companies • Investment career commenced on joining Schroders in 1987 • Chartered Accountant • BSc in Economics, Manchester University https://www.schroders.com/

The Bank On Dividends Podcast
GlaxoSmithKline (GSK) - Stock Analysis

The Bank On Dividends Podcast

Play Episode Listen Later Nov 30, 2021 21:20


Back in action, in this weeks episode of the Bank On Dividends Podcast, Banky takes a deeper look into the Pharmaceutical giant Glaxo Smith Kline: Ticker "GSK". Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's sixth-largest pharmaceutical company. In August 2016, it had a market capitalisation of £81 billion (about US$107 billion), the fourth largest on the London Stock Exchange. But is GSK a stock to consider when building a portfolio you can bank on! Follow on Instagram and Twitter @BankOnDividends https://linktr.ee/BankOnDividends Use the above link for a free share & Also support the Podcast with a one-time donation! Thank You All!

Rádio Gazeta Online - Podcasts
#02 - Boletim Gazeta Online - 09/09/2021

Rádio Gazeta Online - Podcasts

Play Episode Listen Later Sep 10, 2021 3:11


Por unanimidade, a Agência Nacional de Vigilância Sanitária (Anvisa) aprovou o uso emergencial do Sotrovimabe, um anticorpo monoclonal, fabricado pela GlaxoSmithKline (GSK), contra a Covid-19. O monitor Caio Mello (do curso de Jornalismo) explica o que é o medicamento e a forma como ele será administrado. Além disso, ele diz quantos focos de incêndio foram registrados no Cerrado brasileiro no período de 1º de janeiro a 31 de agosto, segundo dados do Programa de Queimadas do Instituto Nacional de Pesquisas Espaciais (Inpe), e as consequências nacionais que o problema pode gerar.

Pops in a Pod
EP 93 - Entrepreneur Parent - Pooja Sardana - Skoodo

Pops in a Pod

Play Episode Listen Later Aug 31, 2021 46:07


Nadir Pop and Peter Pop are back with another episode of Entrepreneur parent with guest, Pooja Sardana. A graduate of IIM - Ahmedabad, Pooja worked at GlaxoSmithKline (GSK) and Hindustan Lever Ltd. before turning entrepreneur with Skoodo. Pooja shares with the Pop duo the origins of Skoodo, the differences between shoes for kids and adults, her experience traveling to over 30 countries with her children and more. Get in touch with the Pops with feedback, questions and more on popsinapod@gmail.com Follow Pops In A Pod Instagram - https://www.instagram.com/popsinapod/ Facebook - https://www.facebook.com/popsinapod Youtube - https://www.youtube.com/channel/UCP3CLTlZuCc9WqgiHjhJ_AQ Nadir currently leads the Business Development division at a digital agency. Prior to this Nadir spent a decade in TV and digital video production – producing, directing, developing content and writing. www.linkedin.com/in/nadir-kanthawala-47249814/ Peter is a marketing guy. He has a decade experience working with companies ranging from startups to public listed companies. www.linkedin.com/in/peterkotikalapudi

The BioProcess Insider Expression Platform
GSK's Digital Twin Approach to Vaccine Development, with Matt Harrison

The BioProcess Insider Expression Platform

Play Episode Listen Later Aug 9, 2021 18:13


A digital twin is a virtual representation that serves as the real-time digital counterpart of a physical object or process. Biopharma giant GlaxoSmithKline (GSK) has adopted this technology to advance its vaccine development and manufacturing division. A year after partnering with Siemens and Atos to pilot a digital twin in order to create a real-time simulation of the entire vaccine manufacturing process, we sat down (virtually, sadly) with Matt Harrison, head of Sciences, Digital Innovation and Business Strategy at GSK to discuss the current status of this project.   Keep up with BioProcess Insider on our website. Follow us on LinkedIn and Twitter: @BioProInsider @BioProcessIntl @Dan5tanton

Si-Suite
Carlos Santiago, Head of Americas for GSK

Si-Suite

Play Episode Listen Later Jul 7, 2021 27:45


Carlos Santiago began his career in GlaxoSmithKline (GSK) as a Site Utilities Engineer at their Manufacturing facility in Cidra, Puerto Rico. With more than twelve years at GSK, he held several roles of increasing responsibility in both the Global Manufacturing & Supply (GMS) and Worldwide Real Estate and Facilities (WREF) organizations. Carlos led the Hispanic/Latino Employee Network (“Conexion Latina”) at GSK which was recognized by Diversity Best Practices in 2018 for their work and impact on hurricane relief efforts in Puerto Rico. His different roles have allowed him to work in many locations as well as travel to more than 30 countries in 4 continents. Carlos is part of the CoRE Tech Advisory Board. He is a graduate of the University of Puerto Rico with a Bachelor of Science in Electrical Engineering and holds a MBA from Universidad del Turabo. When he is not working, he enjoys reading, traveling and running. Carlos is married to Lourdes and has three children; Noah, Gabriella and Carlos Jr. Learn more about GSK here Shout-out: Today's Diversity Leader Shout-out goes to Maya Martinez-Davis, President, U.S. Pharmaceuticals, GSK Music: Intro - Vente by Mamá Patxanga is licensed under a Attribution-Noncommercial-Share Alike 3.0 United States License Outro - Amor Y Felicidad by SONGO 21 is licensed under a Attribution-NonCommercial-ShareAlike 3.0 International License --- Send in a voice message: https://anchor.fm/si-suite/message

Si-Suite
Carlos Santiago, Head of Americas for GSK

Si-Suite

Play Episode Listen Later Jul 7, 2021 27:45


Carlos Santiago began his career in GlaxoSmithKline (GSK) as a Site Utilities Engineer at their Manufacturing facility in Cidra, Puerto Rico. With more than twelve years at GSK, he held several roles of increasing responsibility in both the Global Manufacturing & Supply (GMS) and Worldwide Real Estate and Facilities (WREF) organizations. Carlos led the Hispanic/Latino Employee Network (“Conexion Latina”) at GSK which was recognized by Diversity Best Practices in 2018 for their work and impact on hurricane relief efforts in Puerto Rico. His different roles have allowed him to work in many locations as well as travel to more than 30 countries in 4 continents. Carlos is part of the CoRE Tech Advisory Board. He is a graduate of the University of Puerto Rico with a Bachelor of Science in Electrical Engineering and holds a MBA from Universidad del Turabo. When he is not working, he enjoys reading, traveling and running. Carlos is married to Lourdes and has three children; Noah, Gabriella and Carlos Jr. Learn more about GSK here Shout-out: Today's Diversity Leader Shout-out goes to Maya Martinez-Davis, President, U.S. Pharmaceuticals, GSK Music: Intro - Vente by Mamá Patxanga is licensed under a Attribution-Noncommercial-Share Alike 3.0 United States License Outro - Amor Y Felicidad by SONGO 21 is licensed under a Attribution-NonCommercial-ShareAlike 3.0 International License --- Send in a voice message: https://anchor.fm/si-suite/message

The Gary Null Show
The Gary Null Show - 05.27.21

The Gary Null Show

Play Episode Listen Later May 27, 2021 58:13


I Never Trusted Bill Gates, Nor Should You While leading a Senate investigation, I tracked a corrupt pharmaceutical executive right into the lobby of the much-vaunted Bill and Melinda Gates Foundation—Bill Gates did nothing.   The DisInformation Chronicle,   https://disinformationchronicle.substack.com/p/i-never-trusted-bill-gates-nor-should   The last year has not been kind to Bill Gates.  For two decades, Gates has shoveled out buckets of cash through the Bill and Melinda Gates Foundation to transform himself from despised 1990’s software monopolist to a present-day public health intellectual—a miraculous, money-fueled metamorphosis. But that reputational makeover has stumbled, as a series of critical articles have tarnished Gates’ paid-for golden image and cast doubt on his credibility. However, long before these articles came to light, I already knew that Gates could not to be trusted.  A decade ago, I led a Senate investigation into a multi-billion-dollar diabetes drug sold by GlaxoSmithKline (GSK) that government scientists found to have caused around 83,000 heart attacks. During this federal investigation, I uncovered multiple examples of GSK officials intimidating medical experts who decried the drug’s dangers. A leader in this campaign was GSK’s chairman of research and development, Dr. Tadataka (Tachi) Yamada.  By the time our committee uncovered GSK’s coercion campaign, Yamada had left the company to run Gates’ global health program. And yet, as the media outlets reported on Yamada’s prior role bullying physicians who tried to warn about the drug’s dangers, the Gates Foundation ignored this public outcry and allowed Yamada to maintain his pulpit as global health protector. Twenty years back, journalists scrutinized Gates’ foundation as a vehicle to enrich himself and polish his appearance. But over the years, reporters began to forget Gates’ past and provide him a platform to puff himself up as scientific expert, despite his having no medical or scientific credentials. Bill Gates’ sculpted persona as health policy guru began to wobble last summer, however, precisely because of revelations showing the tools he had used to improve his media cachet. In August 2020, Tim Schwab published an article in the Columbia Journalism Review exposing around $250 million in grants that Gates was throwing at journalism outlets including the BBC, NBC, Al Jazeera, ProPublica, National Journal, The Guardian, Univision, Medium, the Financial Times, The Atlantic, the Texas Tribune, Gannett, Washington Monthly, Le Monde, and the Center for Investigative Reporting.  A later article in The Nation spotlighted Gates’ potential to profit from investments in companies situated to reap a windfall from the COVID pandemic. And another report in The Nation found that Gates’ funding has stifled debate in public health—described as “the Bill chill”—as organizations are reluctant to bite the hand that feeds them. These revelations came as little surprise to me. Back in 2007, I was working as an investigator for the Senate Finance Committee and learned first-hand that Bill Gates does not put the public first. That year, I wrote the Senate Finance Committee’s report showing that, shortly after the GSK diabetes drug Avandia came on the market in 1999, the company attacked and silenced several scientists including Dr. John Buse, a professor of medicine at the University of North Carolina.  GSK began to bully Dr. Buse after he gave talks stating that Avandia might increase cardiovascular problems such as heart attacks. By the time we released the 2007 report, FDA scientists estimated that Avandia had caused approximately 83,000 heart attacks. When Dr. Buse began warning physicians about the drug, Dr. Yamada was at GSK and contacted Dr. Buse’s department chairman to complain. In an email discussing Dr. Buse with GSK’s CEO and other executives, Dr. Yamada wrote:  In any case, I plan to speak to Fred Sparling, his former chairman as soon as possible. I think there are two courses of action. One is to sue him for knowingly defaming our product even after we have set him straight as to the facts—the other is to launch a well planned offensive on behalf of Avandia.... In our report, we released a private email that Dr. Buse later sent a colleague detailing this encounter with GSK: [T]he company’s leadership contact[ed] my chairman and a short and ugly set of interchanges occurred over a period of about a week ending in my having to sign some legal document in which I agreed not to discuss this issue further in public. Dr. Buse ended the email, “I was certainly intimidated by them.... It makes me embarrassed to have caved in several years ago.” Multiple media outlets covered Yamada’s actions, including The Guardian (GSK accused of trying to intimidate critic), NBC News (Diabetes drug probe leads to Gates Foundation), and even Bill Gates hometown newspaper, the Seattle Times (Senate committee turns attention to Gates Foundation official). Months prior to the report’s release, The New York Times also detailed Dr. Yamada’s behavior (Doctor Says He Was Assailed for Challenging Drug’s Safety), as some initial evidence came to light during a hearing in the House.  In response to all this outcry, Bill Gates did... nothing. To put this matter directly under Bill Gates’ nose, I then wrote the Senate Committee’s letter demanding that Dr. Yamada come and brief Senate investigators. Just in case Gates was too distracted with saving the world and playing public health saviour to have noticed the bad press, I had the letter sent directly to the Gates Foundation. When Dr. Yamada showed up for his appointment in Senate Hart, we started with some brief niceties and formalities—typical DC nonsense such as shaking hands, passing out business cards, asking how the plane flight was—before getting down to business. Dr. Yamada’s lawyer then pulled from his briefcase a marked-up copy of a Committee report I had written titled: The Intimidation of Dr. John Buse and the Diabetes Drug Avandia.   We spent about twenty minutes going over the report, as the lawyer explained what Dr. Yamada had done. He then turned the matter over to Dr. Yamada to detail why, many years prior, he had called Dr. Buse's superiors at the University of North Carolina. As Dr. Yamada explained, he wasn't trying to intimidate anyone. Ironically, he even offered up the idea that he had called Dr. Buse's dean at North Carolina, because he was concerned that Avandia might actually be harmful. And if the drug was harmful, Dr. Yamada said, he wanted to know. I almost giggled when he said that. I then asked, "So this is the only time that you can remember calling a university about one of their faculty?" "Yes," he replied. I let him drone on some more, explaining medical research, before I asked him again if he had ever called a university to complain about a professor. Again, he denied doing so, and then started explaining drug development and the regulatory process at the FDA.  I then asked again, "So during all your time at GSK, this is the only incident you can remember where you placed a call to a university about a researcher who raised concerns about one of your products, correct?” I asked. “It was a singular incident in your time at the company?” "Yes," he said. This was the third time that Dr. Yamada had denied making calls to other universities to intimidate academics speaking up about Avandia. I then pulled out copies of GSK emails, showing that Dr. Yamada had called the University of Pennsylvania about physicians there who were worried about drug’s dangers. “Would you like to explain to us about the call you made to the University of Pennsylvania?” I asked. “One of the physicians involved told me, 'It left a really bad taste in my mouth. After that happened, I said that I would never work for a drug company.’ Another physician who was involved told me, 'It’s the kind of thing you imagine happening on TV.'’’ I then slid the emails across the table to him. Dr. Yamada’s attorney jumped up and grabbed the emails saying, “These emails weren't in the report!” “No shit, Counselor,” I thought. “I left these ones out, to see if your client might lie to us. Calm down. Everything's going to be A-O-K....” We then exchanged some more niceties as Yamada “reexplained himself.” Oddly enough, it seems there may have been more than just that one incident at North Carolina, Dr. Yamada said. But I really wasn't interested in listening and started checking my Blackberry. It took a couple more years to go through hundreds of thousands of GSK’s internal documents before we released our final 342-page report in 2010 titled: Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia. But we redacted the names of the scientists at the University of Pennsylvania who Dr. Yamada had harassed for speaking up, because they were still scared about possible retaliation from the drug industry.  After reading the report, Yale cardiologist Harlan Krumholz wrote that it "read like a spy novel.” Analysts at UBS predicted that GlaxoSmithKline could face legal liability of up to $6 billion. The New York Times covered the report on its front page and the CBS News put Yamada in its story’s headline: Meet Glaxo's Fixer -- The Man Who Scuttles Drug Critics With One Phone Call. And still, Bill Gates did nothing. Five months after the 2010 Senate Finance report, GSK agreed to a $460 million settlement with 10,000 Americans who sued the company for withholding Avandia’s heart attack risks. The New York Times editorialized that GSK and its leaders “can’t be trusted to report adverse clinical results fairly.”  Nothing at all happened to Yamada. He remained in his role as global health expert at the Gates Foundation, until he left the following year, in June 2011.  Keeping someone like Yamada to run a global health program has always made me doubt Bill Gates’ commitment to public health. How could anyone have faith in Gates’ judgement after watching him stand idly by as a stream of evidence proved that one of his top lieutenants had a history of corrupt behavior? Since that time, I have never trusted Bill Gates. And neither should you.

#ZigZagHR Brainpickings
Het Randstad Employer Brand onderzoek in een notendop #65

#ZigZagHR Brainpickings

Play Episode Listen Later May 20, 2021 32:58


Het Randstad Employer Brand onderzoek vindt sinds 2000 plaats. Het gaat na waarom werkzoekenden kiezen voor een bepaalde werkgever. Vervolgens wordt een staal van bedrijven voorgelegd die de respondenten moeten beoordelen. Kent men het bedrijf? Zou men er al of niet graag werken? En hoe beoordelen zij het bedrijf op tien geselecteerde criteria?Het onderzoek leert hoe (on)aantrekkelijk bedrijven zijn én waarom. Het levert de bedrijven een unieke benchmark op inzake hun employer brand. Doorheen de tijd is het van oorsprong Belgisch onderzoek geëxporteerd naar 34 landen in vier werelddelen. Anno 2021 blijft het Randstad Employer Brand onderzoek het enige representatieve in dit domein.De slotsom van de vorige studie, gepubliceerd in mei 2020, luidde: “Er is geen ontkomen aan, deze crisis zal zwaar inhakken op de employer brands van bedrijven. Gezien de aard van deze crisis zal dit normaliter nog zwaarder zijn dan bij de vorige recessies.” Die pessimistische toon was gebaseerd op de resultaten in 2009 in de nasleep van de financiële crisis. Maar de gevreesde recessie met jobdestructie bleef (voorlopig) uit.De gemiddelde aantrekkelijkheidsscores blijken niet gedaald. Nagenoeg alle sectoren laten zelfs een gemiddelde stijging optekenen. Geen enkel criterium wordt lager beoordeeld dan vorig jaar. De scores liggen meestal zelfs een kleine fractie hoger. Alleen werkzekerheid blijft ter plaatse trappelen. Dit toont duidelijk aan dat er geen sprake is van een crisisgevoel.Ook de rangschikking waarom men voor een werkgever kiest, ondergaat geen wijzigingen. Werkzekerheid wordt niet belangrijker, het criterium verliest zelfs een plaats en staat nu op vier. De nieuwe coronagerelateerde criteria – thuiswerk en coronaveilig werken – halen een middenpositie. Dat betekent dat loon en voordelen nog steeds het belangrijkste criterium is, dit jaar voor werksfeer en balans werk/privé.De rangschikking van de sectoren blijft ook merkwaardig stabiel. De sectoren die meer dan gemiddeld hinder hebben ondervonden van corona (zoals horeca, toerisme en luchtvaart) houden niet alleen stand, ze gaan er inzake aantrekkelijkheid op vooruit. Dit betekent dat de respondenten de huidige problemen als tijdelijk zien. Ook naar het resultaat van farma werd uitgekeken. Zou de sector profiteren van het vaccinsucces of zou de kritiek op de sector inzake de levering van het vaccin overwegen? De positieve invloed haalt het. De farmasector is voor de twintigste keer (op 21) de meest aantrekkelijke sector. De overwinning wordt nog kracht bijgezet door een tweede plaats bij het criterium CSR. Vorig jaar was dit het enige criterium waar de sector geen top 3 haalde.Het meest verrassende resultaat komt van de luchtvaartsector, die op een zucht van de eerste plaats strandt. De mediasector moet dit jaar tevreden zijn met een derde plaats.Janssen Pharmaceutica is voor de vijfde keer in de geschiedenis van het Randstad Employer Brand onderzoek de meest aantrekkelijke werkgever. Daarmee wordt de nationale trots recordhouder voor DEME en GlaxoSmithKline (GSK), die elk vier keer wonnen.Janssen haalt het redelijk afgetekend voor de nummers twee en drie: Seris en Nike. Voor beide bedrijven is het de eerste keer dat een top 10 positie werd behaald. Nike was in 2020 wel al de meest aantrekkelijke werkgever bij de jongeren, een prestatie die dit jaar wordt herhaald. Seris is de meest aantrekkelijke werkgever in Franstalig België en onttroont RTBF. Bayer en DPG Media vervolledigen de top vijf. Verder in de top 10 valt de sterke prestatie op van Brussels Airlines, dat inzake aantrekkingskracht geen coronaschade heeft opgelopen

Molecular Moments Podcast
Drs. Jolly Mazumdar and Tim Chendrimada: Dreaming Big, Coffee Beans and Self Amplifying RNA

Molecular Moments Podcast

Play Episode Listen Later May 7, 2021 46:07


In today's episode, Chad sits down with guest scientists, Drs. Jolly Mazumdar and Tim Chendrimada, CEO, and CSO of Chimeron Bio. Two different beginnings; one in the sciences studying bugs and infectious diseases and the other in agriculture, specifically coffee beans! They talk to Chad about how their very different paths led them to become a dynamic duo in the next generation of RNA therapeutics. From Tim asking a scientist of Wistar Institute to take a chance on him with no prior experience in medical science to Jolly traveling to the United States for graduate studies in infectious diseases, we learn about how the pair, originally from India, carved their paths to where they are now as veterans in the Pharma industry. Both with careers early on at GlaxoSmithKline (GSK), Jolly’s focus was on biomarkers and innovative early clinical trials in skin cancer drugs and Tim’s on the development side as a bench scientist and the importance of having teamwork when it comes to drug development. These valuable experiences led them to create Chimeron Bio. They talk about how the opportunity to create Chimeron Bio came to be, the importance of challenging yourself and taking risks you believe in, talking to investors, their technology pipeline and self-amplifying RNA COVID-19 vaccine that protects against new variants. See omnystudio.com/listener for privacy information.

TẠP CHÍ KINH TẾ
Tạp chí kinh tế - Vac-xin chống Covid-19 : Ai đang kiểm soát thị trường ?

TẠP CHÍ KINH TẾ

Play Episode Listen Later Apr 20, 2021 9:27


Ngành sản xuất vac-xin nhờ virus corona lãi bạc tỷ. Chìa khóa của đà phục hồi kinh tế cho thế giới sau hơn một năm chống chọi với đại dịch Covid-19 trong tay một số rất ít các viện bào chế. Không dễ tìm ra một loại thuốc mới để trị một con siêu vi mới : ở mỗi chặng nghiên cứu, sản xuất, đóng chai, phân phối… các nhà sản xuất đều phải vượt qua 1001 thử thách. Thuốc tiêm chống Covid-19 là một sản phẩm tuân thủ luật cung cầu của thị trường ? Nhu cầu về thuốc tiêm chủng chống Covid-19 cho toàn nhân loại ước tính trên dưới 14 tỷ liều. Trên thực tế cho đến cuối 2020, tất cả các nhà máy trên thế giới chỉ có thể sản xuất 3,5 tỷ liều vac-xin. Làm thế nào để trong một thời gian rất ngắn nhân lên gần gấp 4 lần mức cung ứng ? Một số rất ít các nhà sản xuất Trên đài RFI tiếng Pháp, kinh tế gia Nathalie Coutinet giảng dậy tại đại học Paris 13 chuyên nghiên cứu về ngành công nghiệp thuốc trước hết điểm qua vài nét tiêu biểu của một thị trường rất đặc biệt này : « Ngành công nghiệp bào chế vac-xin chiếm 5 % tổng doanh thu thị trường thuốc men toàn cầu, tức là khoảng 5 % trong số 1000 tỷ đô la. Kế tới, đây là một lĩnh vực tập trung trong tay một số rất ít các nhà sản xuất. Trên thế giới hiện có 4 tập đoàn lớn chế tạo vac-xin và số này kiểm soát đến 80 % thị phần. Trong số 4 công ty tên tuổi thống lĩnh toàn cầu, thời gian gần đây Pfizer được nhắc đến nhiều hơn cả. Kế tới là Sanofi, rồi GlaxoSmithKline (GSK) và sau cùng là Merk ». Covid-19 thay đổi cục diện ngành công nghiệp dược phẩm thế giới  Chỉ một con siêu vi cũng đủ để từ gần một năm qua, đại đa số các hoạt động ngoại giao đều thực hiện qua cầu truyền hình. Tệ hơn cả là mùa xuân năm ngoái, hơn một nửa nhân loại bị giam hãm trong nhà : kinh tế bị tê liệt, các nhà máy phải đóng cửa, dây chuyền cung ứng bị gián đoạn... Ngành dịch vụ từ nhà hàng đến khách sạn hay du lịch, đời sống xã hội và văn hóa thể thao đâu đâu cũng bị thu hẹp lại. Ngoại trừ một vài trường hợp riêng lẻ như của Việt Nam hay Đài Loan, Trung Quốc, Âu, Mỹ đồng loạt báo động kinh tế suy sụp ở mức « nguy hiểm nhất từ sau Thế Chiến Thứ Hai ». Trong tình cảnh cấp bách đó ngành dược phẩm lao vào cuộc chạy đua tìm vac-xin mới để phòng ngừa một căn bệnh mới. Trong chưa đầy một năm từ Trung Quốc đến Nga, châu Âu nhưng đứng đầu là Mỹ đã về đến đích : Nga hãnh diện với Sputnik V, Trung Quốc ồ ạt xuất khẩu vac-xin của Sinopharm và SinoVax. Liên doanh Anh và Thụy Điển AstraZeneca giao hàng không kịp cho Liên Hiệp Châu Âu, Mỹ và cả chương trình Covax để cung cấp thuốc cho các nước nghèo. Hoa Kỳ có đến ba hãng chế tạo vac-xin trúng số độc đắc đó là Moderna, Johnson&Johnson và Pfizer. Ông khổng lồ trong ngành dược phẩm này đã hiện diện trên thị trường từ hơn 170 năm nay và hiện có một đội ngũ hơn 80 ngàn nhân viên trên khắp thế giới. Chuyên gia kinh tế Nathalie Coutinet nhắc đến bước đột phá quan trọng nhất trong đối với nền công nghiệp dược phẩm của thế giới trong đại dịch Covid-19 :    « Công nghiệp sản xuất vac-xin trước đây chủ yếu phát triển nhờ công nghệ hóa học, có nghĩa là không sử dụng công nghệ sinh học. Tuy nhiên rất nhiều viện bào chế từ nhiều năm qua đã đẩy mạnh nghiên cứu trong lĩnh vực này đặc biệt là phương pháp dùng vật liệu di truyền ARN thông tin. Công nghệ này chủ yếu được phát triển nhờ các công ty khởi nghiệp với hai mục tiêu ban đầu là tìm ra vac-xin chống ung thư và chống lại siêu vi HIV/AIDS. Lĩnh vực dược phẩm đang trải qua một giai đoạn chuyển biến quan trọng và virus corona chủng mới đã bắt đầu làm thay đổi cục diện của ngành chế tạo vac-xin trong một thời gian dài. Công nghệ ARN đang mở ra nhiều chân trời mới và đang cấu tạo nên một trật tự mới trong ngành dược ». Về phần giáo sư Pierre - Yves Geoffard, trường Cao Đẳng Khoa Học Xã Hội Pháp EHESS, ông lưu ý virus corona đã làm đảo lộn trật tự trên bàn cờ của nền công nghệ dược phẩm vốn trong tay bốn đại gia là Pfizer của Mỹ, Sanofi của Pháp, GSK của Anh, và Merk của Đức :  « Còn hơi sớm để nói tới một cuộc cách mạng, nhưng lĩnh vực sản xuất vac-xin đang có nhiều chuyển biến quan trọng và rất nhanh chóng. Mô hình phát triển trong ngành dược phẩm thay đổi nhanh nhờ đã có nhiều những phát minh mới. Thông thường một hãng lớn mua lại các công ty khởi nghiệp, hoặc mua hẳn bằng sáng chế của các hãng nhỏ. Nhưng lần này đáng chú ý là hãng lớn và lâu đời như Pfizer đã không mua lại bằng sáng chế của BioNTech hay mua lại luôn BioNTech – đây là một hãng của Đức không quá nhỏ nhưng tương đối là khá mới trong ngành. Pfizer chọn cùng với BioNTech bào chế vac-xin chống Covid-19. Có thể nói đây là một hình thức cộng các kiểu mới giữa hãng dược phẩm của Mỹ và của Đức. Thêm một điểm cần lưu ý khác, đó là trong số 4 đại công ty chế tạo vac-xin thống lĩnh thị trường toàn cầu, chỉ có một mình Pfizer tìm ra thuốc chích ngừa chống virus corona. Ba vac-xin khác được ba hãng mà tôi tạm gọi lã những « lính mới » trong ngành làm ra : Moderna, cũng của Mỹ, nhưng là một công ty rất nhỏ. AstraZneca của Anh và Thụy Điển chưa từng bào chế bất kỳ một loại vac-xin nào. Cuối cùng, Johnson&Johnson thì chỉ có một thị phần rất khiêm tốn ». Covid-19, gà để trứng vàng Trong cuộc chạy đua tìm kiếm « thuốc tiên » giải cứu cho nhân loại thoát khỏi nanh vuốt của siêu vi Sars-Co-V-2 đương nhiên những thí sinh về đầu đã giành được những phần thưởng đắt giá nhất. Trong một sớm một chiều Moderna một công ty mới tham gia thị trường dược phẩm thế giới từ 2010 và chưa bao giờ làm ăn có lãi, với hơn 800 nhân viên, trở thành một « đấng cứu tinh » : theo các số liệu công bố tháng 2/2021 một công ty mới chỉ hôm qua còn đứng trong bóng tối thông báo ký hơn 15 tỷ đô la hợp đồng để cung cấp 310 triệu liều vac-xin cho Liên Hiệp Châu Âu cho năm nay và thêm 150 triệu cho năm tới. Mỹ đặt mua 300 triệu liều Nhật Bản là 50 triệu… Virus corona « thổi » cổ phiếu của công ty này lên cao đến hơn 240 % so với cùng thời kỳ năm ngoái. Hành trình của loại vac-xin do liên doanh của Anh và Thụy Điển cộng tác với đại học Oxford không được thanh thản như thuốc sử dụng công nghệ ARN nhưng dự kiến doanh thu của AstraZeneca trong năm 2021 đạt 1,8 tỷ đô la và 2,7 tỷ vào năm tới. Đây là một kỳ công đối với một hãng dược phẩm chưa từng lao vào thị trường chế tạo và sản xuất vac-xin. Về phần Johnson&Johson nhờ chỉ cần một lượt chích và với giá chưa đầy 10 đô la một liều, đơn đặt hàng của tập đoàn có trụ sở tại New Jersey này hiện tại lên tới hơn 1,2 tỷ liều vac-xin.  Sau cùng cặp bài trùng Pfizer BioNTech vừa trúng số độc đắc : doanh thu trong năm nay dự trù đạt 12,5 tỷ đô la mức lãi của tập đoàn ước tính từ « 25 đến 30% » và có thể « là còn cao hơn gấp đôi so với dự phóng ». Là một cây đại thụ trong ngành, cổ phiếu của Pfizer tăng giá 7 % trong năm vừa qua. Riêng với BioNTech, mới chỉ bắt đầu hoạt động từ 2008, thì công nghệ ARN là một sự bất ngờ và là thành công ngoài mong đợi. Do vậy cổ phiếu của BioNTech đã có một bước « đại nhảy vọt ». Marie Ange Saraka Yao trên đài RFI nói đến một thay đổi quan trọng khác virus corona đem lại đó là do đại dịch hoành hành cùng một lúc khắp địa cầu, nhu cầu về vac-xin vượt ngoài khả năng của cả thế giới. Đây là một cơ hội bằng vàng cho một số công ty thuốc của các nền kinh tế đang trỗi dậy : « GAVI là hiệp hội bao gồm nhiều thực thể có liên quan đến thuốc vac-xin như là các cơ quan quốc tế, các viện nghiên cứu, các tổ chức đa quốc gia như WHO, các hãng dược phẩm, … Việc có thêm những hãng mới gia nhập câu lạc bộ các nhà sản xuất vac-xin là một điều đáng mừng vì hiện tại, các nhà sản xuất có thể cung cấp ba tỷ rưỡi liều vac-xin, với đại dịch nhu cầu tăng vọt lên thành 14 tỷ. Làm thế nào đáp ứng nhu cầu tăng đột ngột đó trong một sớm một chiều ? Hiệp hội GAVI khi được thành lập vào năm 2000 làm việc với 5 nhà sản xuất. Giờ đây GAVI hợp tác với 18 viện bào chế mà trong đó có nhiều hãng xuất xứ từ các nền kinh tế đang trỗi dậy. Những hãng chinh phục được thị trường chủ yếu nhờ công nghệ sinh học, họ đem lại một phương pháp làm việc mới và kèm theo đó là những công trình nghiên cứu và phát triển mới. Số này cộng tác với những cái tên tuổi đã quá quen thuộc trong ngành – điển hình là sự cộng tác giữ BioNTech với Pfizer. Ngoài ra chúng ta thấy trong trường hợp của AstraZeneca đây là một sự hợp tác ở cấp toàn cầu. Liên doanh Anh và Thụy Điển này hiện diện tại nhiều nước ở Châu Âu, tại Ấn Độ hay Hàn Quốc. Hơn bao giờ hết chúng ta cần tất cả các quốc gia trên thế giới chung tay để đáp ứng nhu cầu cùng một lúc cho cả thế giới ».  Ấn Độ nhà thuốc của thế giới Ấn Độ từ nhiều năm qua đã trở thành nhà sản xuất thuốc và vac-xin lớn nhất thế giới. Đây cũng là nơi mà hầu hết các tập đoàn dược phẩm đều đặt cơ sở sản xuất. Covid-19 xác định lại điều đó. Có điều ngay cả đến nhà cung cấp này cũng đã bị bất ngờ vì virus corona chủng mới như thông tín viên Sébastien Farcis từ New Delhi tường thuật :    « Andar Poonawalla hiện là một trong những nhân vật quan trọng nhất tại Ấn Độ. Ông là tổng giám đốc tập đoàn dược phẩm Serum Institute of India, công ty sản xuất vac-xin lớn nhất trên thế giới và là nguồn cung cấp thuốc của AstraZeneca cho toàn cầu. Cách nay vài tháng khi mà thuốc của liên doanh Anh và Thụy Điển còn chưa được phép sử dụng, giám đốc công ty đã bắt đầu ngừng sản xuất các loại vac-xin khác để dành hết mọi ưu tiên cho thuốc của AstraZeneca. Ông nhấn mạnh, quyết định này có được nhờ tập đoàn không lệ thuộc vào các ngân hàng hay cổ đông mà hoàn toàn độc lập về mặt tài chính. Trước đại dịch Covid-19, mỗi năm Ấn Độ sản xuất hai tỷ rưỡi liều vac-xin, tương đương với hơn 50 % nhu cầu tiêu thụ trên thế giới. Năng suất của Ấn Độ trong năm nay tiếp tục tăng thêm hơn 40 % so với bình thường. Hiện tại, Ấn Độ là quốc gia sản xuất vac-xin chống Covid-19 lớn thứ nhì - chỉ thua có Mỹ. Sắp tới đây Ấn Độ nhận thêm hợp đồng sản xuất vac-xin Sputnik V của Nga và Janssen của hãng Mỹ Johnson&Johnson. Milan Patel chủ tịch hiệp hội các tập đoàn công nghiệp sản xuất vac-xin Ấn Độ nêu bật những lợi thế của quốc gia Nam Á này : trên toàn quốc có 1.500 nhà máy được chứng nhận đáp ứng các tiêu chuẩn của Tổ Chức Y Tế Thế Giới. Ở ngoài lãnh thổ Mỹ, Ấn Độ là nơi thứ nhì Cơ Quan Y Tế Hoa Kỳ tín nhiệm nhất. Theo ông Patel, điều đó cho thấy rõ uy tín của Ấn Độ với cộng đồng quốc tế về khâu sản xuất vac-xin. Ấn Độ xuất khẩu 64 triệu liều thuốc tiêm chống Covid-19 cho thế giới, trong đó 18 triệu nhằm phục vụ chương trình CoVax cung cấp cho các nước nghèo. Trong bối cảnh dịch bệnh bùng phát trở lại với đà quá nhanh, New Delhi đã cấm xuất khẩu vac-xin, dành ưu tiên cho thị trường nội địa. Dù vậy giới trong ngành cho biết với nhịp độ tiêm chủng 4 triệu người mỗi ngày, từ nay đến giữa tháng 6/2021 Ấn Độ sẽ có thể cung cấp thuốc trở lại cho thế giới. AstraZeneca cảnh cáo New Delhi về nghĩa vụ xuất khẩu vac-xin như tập đoàn Serum Institute of India đã cam kết ».

ReConnectingTHEDots Podcast
#Ep15_ The Status of COVID-19, with Dr. BILIKIS

ReConnectingTHEDots Podcast

Play Episode Listen Later Feb 12, 2021 54:53


it is indeed a known fact that entire world have been ravaged with a severe viral infectious disease that has claimed millions of lives. Take a Listen to this insightful and informative "HEALTH & WELLNESS" segment with Dr. Bilikis - Medical Analytics Director for US Medical Affairs at GlaxoSmithKline (GSK). --- Send in a voice message: https://anchor.fm/afolarin-ani/message

The Institute talks
The Institute talks...to Nikki Greaves

The Institute talks

Play Episode Listen Later Feb 10, 2021 10:28


Part of our apprentice panel podcasts, Jamilah Simpson our apprentice panel host interviews member, Nikki Greaves.   Nikki Greaves, 20, is currently completing her level 5 laboratory science apprenticeship with GlaxoSmithKline (GSK).   Transcript Jamilah Simpson: Hi, I'm Jamilah Simpson the Multiverse Community Programs and Networks Associate. I joined Multiverse early last year after completing my digital marketing qualification as an apprentice at Google. I'm also an apprentice panel member and your host for this podcast. Today we're joined by Nikki. Nikki did you quickly want to intro yourself before we get started Nikki Greaves: Hi, I'm Nikki a laboratory science apprentice for GSK currently in my third year now. Jamilah Simpson: Thank you, Nikki, we're so glad to have you here today. So, I've got a few questions for you. Starting with, as we both chose the apprenticeship route, I think we can both agree that there are so many benefits to them. What drew you into your apprenticeship? Nikki Greaves: So it's weird actually, I knew in sixth form that I wanted to go into a sciencey kind of lab-based career, and I was actually really set on doing a Biomed kind of degree at uni. My school was very like forward at pushing us down the uni kind of route, and it was only one day when I was looking at the government website that I actually stumbled upon the GSK apprenticeship,  and I was actually really intrigued. Because probably like quite a few other people I just assumed that apprenticeships were like carpentry and plumbing. Obviously, that sounds really bad, but I really didn't have much of a clue of what apprenticeships actually were. So when I saw this advertisement basically being like you can have a degree and learn hands-on I was pretty much like wow, this is actually exactly what I want. Because obviously the whole sitting in lectures, and that's just not how I learn and I was actually really worried about that aspect of uni. So actually, getting a hands-on was so much better for me, so I applied immediately. Jamilah Simpson: I had the exact same reaction because I didn't have a lot of information about apprenticeships when I was at college either. When I found out that there's so many different industries that you can go in to, I got really excited. I actually found my apprenticeship through my mum, so similar to you, my school wasn't helpful at all. Nikki Greaves: I honestly didn't even know they existed like at all. Jamilah Simpson: So Nikki your apprenticeship sounds really, really interesting and I'd love to know more about what you do day-to-day. Nikki Greaves: So, the usual day for me consists of helping my team set up and run studies. Where we basically look at how different compounds work. So how they work in the body if they're going to the right places and doing what we want them to do basically. A particularly interesting project that I've been involved in, was working on an HIV project where we looked at the potential for a treatment to take place twice a year rather than the current treatment regime, which is administered monthly. Jamilah Simpson: Wow sounds like pretty important stuff. So as you know we've all been going through a really tough time over the past year as a nation. Being a laboratory scientist, have you had an opportunity to support with COVID- 19? Nikki Greaves: Unfortunately not. I would have absolutely loved to be involved, but my team and I have just had a lot of work that's ongoing. Like I have been in work as a key worker, but it hasn't been COVID involved. Although I have actually signed up to be a volunteer for the mass vaccinating and actually GSK like alongside the NHS organised that for some of the employees. So I'm doing that. Jamilah Simpson: That's amazing. You mentioned that you're a key worker does that mean that you still go into your place of work? Nikki Greaves: Yeah, so pretty much throughout the lockdown we were going in on a like shift kind of pattern. So that obviously there's like a limited amount of people on-site, but yeah pretty much just working our way through it. Because obviously a lab base, I can't exactly work from home very much. As much as I try and say my coursework, I could get on with my coursework. But yeah I know we've just been doing shifts really. Jamilah Simpson: Well I can imagine that must be really difficult to go through Nikki Greaves: it's actually. I feel like it gives regularity to the days. It is a bit difficult to like, make a routine because sometimes you're called in last minute, or sometimes then you're not needed. So, that's probably the hardest bit, but other than that it's still nice to be able to talk to people other than my housemates, as much as I love them. Jamilah Simpson: Yeah, I really struggled to maintain that routine when I was working from home and I've recently started coming back into the office a few days a week. It's just nice to have that commute. It's something that I never thought that I'd miss having that commute in the morning and actually getting on a train. I really missed that during the first lockdown. So now I'm getting back into it it's just nice to have that distinction between work. So on to our next question. What would you like to do next after you've finished your apprenticeship? Nikki Greaves: So, I'm currently doing a level 5 apprenticeship. So I'm in my third year now, so hopefully, fingers crossed if all goes well, in August time I'll get my bioscience foundation degree. Then I'm hoping to basically stay on at GSK for another year and a bit, to get a level 6 apprenticeship, and get my full bachelor's degree, so hopefully that. As for after that I'm just hoping I can get a full-time job at GSK, and maybe explore different departments. Because I'm still not really sure what I want to particularly do. I think the science industry is so like varied, and so wide. I think there's just so much to explore still. So we'll have to see. Jamilah Simpson: I think it's amazing that you're thinking about going on to a level 6. I didn't even know that existed until a few weeks ago. The fact that you've also like kind of got a plan in place I really respect that. I'm not much of a planner I just like take things as it comes. I think I'm going to start definitely thinking about like the 5-year plan and the 10-year plan going forward. Nikki Greaves: I feel like I need to be more that. I'm too like plan it all, plan it all, I really need to kind of take things on the chin a bit more. Jamilah Simpson: We can help each other out we can balance. So we know that you're part of the apprentice panel, along with myself. Why did you decide to join the panel in the first place? Nikki Greaves: Well, I just think it's a great opportunity. I think being able to work with people, who are like-minded, who also have a passion for apprenticeships. I just think that was a great opportunity and it also gives me an opportunity to give maybe apprentices that don't have a voice, like a platform for them to speak out, and give their opinion. So, I just thought it was a great opportunity to have. Jamilah Simpson: It's quite an empowering experience, isn't it? Something that we're working on in the apprentice panel, is the best practice guidance for apprenticeships. I believe that you're in the induction process. Nikki, can you tell me why that part is so important? Nikki Greaves: I just feel like the induction of anything is just important. I mean like it's the part that sets you up. It's the part where you get told what to expect, and the experiences that you'll get, and what you'll learn. So I just really feel like a great induction can have such an impact, and it will really set you up for the rest of your apprenticeship. Jamilah Simpson: Yeah, definitely, I agree. Out of curiosity what was your induction process like? Nikki Greaves: So, I went on-site, like a month before, and it didn't go very well. I actually was so nervous the night before that I didn't sleep very well. Then in the morning, because I lived quite far away, and I actually commuted in the morning. It was like an hour drive, so I had barely eaten, like a banana, so and then I had a really long journey. So I was absolutely knackered, and I actually fainted. Jamilah Simpson: Oh my god, that's awful. Nikki Greaves: As it was it was, actually quite good. On my first day, because it kind of was an ice breaker. I was like the girl that fainted if you remember me. So, it kind of worked out in the end. As embarrassing as it was. Jamilah Simpson: Oh wow, that sounds very intense. By being on the apprentice panel what do you want to achieve? Nikki Greaves: Well, like I said, just to have a platform for apprentices to raise their opinions. Also, to just help with improving the overall apprentice experience. I feel like there's such a range of different experiences, and I feel like making that all like merge, and all actually go together, so that everyone has similar experiences. I think that all that's a really good thing to work towards. Jamilah Simpson: Definitely. I 100% agree. Finally, you briefly mentioned the fact that you didn't really have support from school when you were looking for your apprenticeship, and you were quite surprised when you found out the opportunity that you're in now. Have you got any advice for people thinking about doing an apprenticeship? Nikki Greaves: Yeah, so I would just say explore apprenticeships online, on government websites, there's just so many actually available that people don't realise. So I just say do your research. It's a really great alternative to university, you get to network with so many professionals in your field. I just feel like it opens so many doors. So I just say go for it, research it, apply. Jamilah Simpson: Yeah, I think we both have, like biased opinions, because we both, like you're on an apprenticeship at the moment, and I've completed mine last year. So we only have like good things to say about apprenticeships. But I definitely agree with your point about research and making sure that you know what you're getting yourself into before you actually commit. So, thank you. That's all we have time for in today's episode. I want to say a huge thank you to our guest Nikki for taking the time to tell us about your apprenticeship experience and being so open and honest with me today. Thanks for listening, and look out for our next episode. Bye.

Health Professional Radio - Podcast 454422
GSK's BENLYSTA (Belimumab) Treatment for Lupus and Adult Active Lupus Nephritis

Health Professional Radio - Podcast 454422

Play Episode Listen Later Feb 7, 2021 8:57


Dr. Tania Gonzalez-Rivera, MD, BENLYSTA Global Medical Affairs Lead at GlaxoSmithKline (GSK) discusses the recent FDA approval of BENLYSTA (Belimumab) the first and only approved biologic treatment for both lupus and adult patients with active lupus nephritis who are receiving standard therapy. This approval builds on 10 years of clinical evidence. Tania C. González-Rivera, MD, BENLYSTA Global Medical Affairs Lead at GlaxoSmithKline (GSK), has a deep breadth of experience in Medical Affairs spanning a variety of therapeutic areas. As a board-certified rheumatologist with clinical expertise in systemic lupus erythematosus (SLE) and other complex autoimmune diseases, she also has extensive knowledge regarding clinical trials and a background in translational research for SLE and lupus nephritis (LN). Dr. González-Rivera earned her Doctor in Medicine and completed her Residency in Internal Medicine at the University of Puerto Rico School of Medicine, and completed her Rheumatology Fellowship at the University of Michigan.

Running is Cheaper Than Therapy
MD/PhD Covid Conversations with Dr Q

Running is Cheaper Than Therapy

Play Episode Listen Later Dec 9, 2020 52:10


Are the vaccines that will be released to the public safe? Have they been tested with diversity in mind? In order to make the best decisions for your health, it's best to know and understand the process of how drugs and vaccines are developed. In this episode, I bring in Dr. Marquita Qualls-- a chemist with a background in drug development. Dr. Qualls professional career began at GlaxoSmithKline (GSK), one of the leading pharmaceutical companies in the world. During nearly a decade at GSK, she held roles of increased global responsibility spanning drug development, technology evaluation, program management, strategy, and people development. Hopefully, this episode will help you make better-informed decisions regarding COVID, and the vaccines during these times of uncertainty. Episode Highlights: About Dr. Marquita Qualls How she got her degree and how long it took Dr Q's obstacles in getting her PhD as the only black woman and how she dealt with it Her experience with GlaxoSmithKline The process of drug development Inclusivity and diversity in clinical trials Covid from those in the perspective of one in the pharmaceutical industry Her shifting careers and gaining an entrepreneurial mindset Going for your dreams About our Guest: Dr. Marquita M. Qualls has over 20 years of leadership experience in consulting, coaching, and motivating people who want to produce order out of their chaos. Though a scientist by training, she commands a masterful understanding of the interpersonal skills needed to thrive in today’s fast-paced and competitive business environment. Marquita made history by becoming the first female African-American to receive her Ph.D in chemistry from Purdue University. Connect with Dr. Marquita Qualls:  Entropia Consulting Dr. Marquita Qualls on Twitter Dr. Marquita Qualls on LinkedIn Dr. Marquita Qualls on Facebook Dr. Marquita Qualls on Instagram — Did you enjoy today’s episode? Please subscribe and leave a review. If you have questions, comments, or possible show topics, email runningischeaperthantherapyolb@gmail.com. To subscribe and review use one links of links  below  Apple Spotify Google  Get a copy of the book  Running Is Cheaper Than Therapy: A Journey Back to Wholeness

Invest Diva
Top Undervalued Stocks To Buy Now: 5 Dividend Paying Covid-19 Stock Investment Strategies

Invest Diva

Play Episode Listen Later Dec 9, 2020 17:16


Dividend Talk
EP #16 - Q3 Dividend Portfolio review

Dividend Talk

Play Episode Listen Later Oct 3, 2020 56:56


this week we reviewed both our portfolios in relation to its Q3 performance. We started the show with the news of the week EMF asks European DGI about his opinion of Unilever's HQ move to the UK. eDGI shares his historical perspective for this move and why it makes sense to choose the UK. He does bring up the point though about its dividend reliability if Unilever starts to use the British Pound as their base currency. Will it mean that Euro investors will be exposed to additional currency risk? https://www.thisismoney.co.uk/money/m... EMF also shares the recent news about Shell. Shell is planning to cut up to 9000 jobs and we talk about what it might mean for the company. https://edition.cnn.com/2020/09/30/bu... EDGI shares his thoughts about Bayer. Bayer just announced an adjusted performance outlook. It also gave a heads-up about upcoming impairment charges in its agriculture business. What to do with Bayer, that's really the question. https://www.investor.bayer.com/en/nc/... Last but not least, EMF and eDGI also share their support for Beurswolf's S&P500 major league. They find it a very interesting and competitive contest. They're recommending everyone to join the contest via Twitter. https://beurswolf.com/2020/09/28/sp50... Main Topic: The main topic was about reviewing their portfolios and how it performed in Q3 2020. eDGI's income from dividend was still growing strongly while his absolute portfolio value stayed flat. This was mainly due to a drag down in his Oil stocks and net new monthly contributions. EMF mentioned that Q3 was all about cleaning up his portfolio. He sold 15 positions and started to put strength back in his portfolio by focusing on high quality positions, Also EMF enjoyed a strong growth in his year-over-year dividend income. Listeners Questions: This week we answered the below questions: Andrew - I have been assessing Glaxosmithkline (GSK) and have opened a small position. What do you think of this as a good pharma purchase. Danny - Thoughts on how Trump catching Covid might affect the presidential race along with the stock market ? Centrino - $XOM : buy now for its high divi (oil is still there for many years) ? Or run away, because future is electric and gaz? Letuscompound - Thoughts on our favorite laggard Shell? 30 min rant from edgi please :) Phil - Is taxation a reason for you not to invest in something Gerry Farrel - Any thoughts on Neste Oyj? Neste Oyj is a Finland-based company engaged in the refining and marketing of petroleum and petroleum products Last but not least, we both shared our stock pick of the week. While you're at it, don't forget to hit the Subscribe and Like button

IG Trading the Markets
Coronavirus vaccine: who is leading the race?

IG Trading the Markets

Play Episode Listen Later Jul 29, 2020 10:55


As Sanofi and GSK secure the deal to supply up to 60 million potential vaccines to the UK government, we are looking at the pharma stocks involved in the race. IGTV’s Victoria Scholar is joined by IG’s Josh Warner, who talks us through some of the companies, including Pfizer, AstraZeneca, and Moderna. Josh explains why governments are eagerly buying stock in advance, and reminds that there are no vaccines from previous versions of coronavirus. The two discuss the opportunities for investors in the current uncertain environment. Follow us on Twitter @IGTV Fundamentals and charts: GlaxoSmithKline (GSK) Sanofi AstraZeneca Moderna Pfizer (All Sessions) BioTech